{"id":"https://openalex.org/W2096906176","doi":"https://doi.org/10.1517/13543784.2014.918604","title":"Selective JAK inhibitors in development for rheumatoid arthritis","display_name":"Selective JAK inhibitors in development for rheumatoid arthritis","alternate_titles":[],"publication_year":2014,"publication_date":"2014-05-12","ids":{"openalex":"https://openalex.org/W2096906176","doi":"https://doi.org/10.1517/13543784.2014.918604","mag":"2096906176","pmid":"https://pubmed.ncbi.nlm.nih.gov/24818516"},"language":"en","primary_location":{"id":"doi:10.1517/13543784.2014.918604","doi":"https://doi.org/10.1517/13543784.2014.918604","is_oa":false,"landing_page_url":"https://doi.org/10.1517/13543784.2014.918604","pdf_url":null,"source":{"id":"https://openalex.org/S131064935","display_name":"Expert Opinion on Investigational Drugs","issn_l":"1354-3784","issn":["1354-3784","1744-7658"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Investigational Drugs","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2096906176"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5028458938","display_name":"Peter Norman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Peter Norman","raw_affiliation_strings":["Norman Consulting, 18 Pink Lane, Burnham, Bucks, SL1 8JW, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Norman Consulting, 18 Pink Lane, Burnham, Bucks, SL1 8JW, UK","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5028458938"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":2.637,"has_fulltext":false,"cited_by_count":164,"citation_normalized_percentile":{"value":0.92701863,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":100},"biblio":{"volume":"23","issue":"8","first_page":"1067","last_page":"1077"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.9868000149726868,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.9868000149726868,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11503","display_name":"Cytokine Signaling Pathways and Interactions","score":0.009200000204145908,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11616","display_name":"Autoimmune and Inflammatory Disorders Research","score":0.002099999925121665,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/jak-inhibitors","display_name":"JAK inhibitors","score":0.9940000176429749},{"id":"https://openalex.org/keywords/rheumatoid-arthritis","display_name":"rheumatoid arthritis","score":0.996999979019165},{"id":"https://openalex.org/keywords/baricitinib","display_name":"baricitinib","score":0.8690000176429749},{"id":"https://openalex.org/keywords/filgotinib","display_name":"filgotinib","score":1.0},{"id":"https://openalex.org/keywords/tofacitinib","display_name":"tofacitinib","score":0.9120000004768372},{"id":"https://openalex.org/keywords/peficitinib","display_name":"peficitinib","score":0.843999981880188},{"id":"https://openalex.org/keywords/cytokine-receptor-signalling","display_name":"cytokine receptor signalling","score":0.7929999828338623},{"id":"https://openalex.org/keywords/acr20-response","display_name":"ACR20 response","score":0.7720000147819519},{"id":"https://openalex.org/keywords/adverse-effects","display_name":"adverse effects","score":0.3630000054836273}],"concepts":[{"id":"https://openalex.org/C2778886723","wikidata":"https://www.wikidata.org/wiki/Q3530324","display_name":"Tofacitinib","level":3,"score":0.8618534803390503},{"id":"https://openalex.org/C112392421","wikidata":"https://www.wikidata.org/wiki/Q903451","display_name":"Janus kinase","level":3,"score":0.8075353503227234},{"id":"https://openalex.org/C2777575956","wikidata":"https://www.wikidata.org/wiki/Q187255","display_name":"Rheumatoid arthritis","level":2,"score":0.7859461903572083},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6827057600021362},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.5806154012680054},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.5170720219612122},{"id":"https://openalex.org/C2775855021","wikidata":"https://www.wikidata.org/wiki/Q968436","display_name":"Cytokine receptor","level":3,"score":0.48371249437332153},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4737870395183563},{"id":"https://openalex.org/C130523297","wikidata":"https://www.wikidata.org/wiki/Q14914487","display_name":"Tyrosine kinase 2","level":5,"score":0.46429452300071716},{"id":"https://openalex.org/C35174551","wikidata":"https://www.wikidata.org/wiki/Q7660502","display_name":"Syk","level":4,"score":0.4517275393009186},{"id":"https://openalex.org/C2777077863","wikidata":"https://www.wikidata.org/wiki/Q170990","display_name":"Arthritis","level":2,"score":0.43553197383880615},{"id":"https://openalex.org/C2778690821","wikidata":"https://www.wikidata.org/wiki/Q212354","display_name":"Cytokine","level":2,"score":0.3335878252983093},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.30968940258026123},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.281873494386673},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.25438976287841797},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.1373128890991211},{"id":"https://openalex.org/C180361614","wikidata":"https://www.wikidata.org/wiki/Q7202242","display_name":"Platelet-derived growth factor receptor","level":4,"score":0.09523606300354004},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.062363237142562866},{"id":"https://openalex.org/C2775960820","wikidata":"https://www.wikidata.org/wiki/Q408378","display_name":"Growth factor","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000893","descriptor_name":"Anti-Inflammatory Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000893","descriptor_name":"Anti-Inflammatory Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000893","descriptor_name":"Anti-Inflammatory Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D001172","descriptor_name":"Arthritis, Rheumatoid","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001172","descriptor_name":"Arthritis, Rheumatoid","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015195","descriptor_name":"Drug Design","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015398","descriptor_name":"Signal Transduction","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D018501","descriptor_name":"Antirheumatic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D018501","descriptor_name":"Antirheumatic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D018501","descriptor_name":"Antirheumatic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D053612","descriptor_name":"Janus Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D053612","descriptor_name":"Janus Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1517/13543784.2014.918604","doi":"https://doi.org/10.1517/13543784.2014.918604","is_oa":false,"landing_page_url":"https://doi.org/10.1517/13543784.2014.918604","pdf_url":null,"source":{"id":"https://openalex.org/S131064935","display_name":"Expert Opinion on Investigational Drugs","issn_l":"1354-3784","issn":["1354-3784","1744-7658"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Investigational Drugs","raw_type":"journal-article"},{"id":"pmid:24818516","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24818516","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert opinion on investigational drugs","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.8371999859809875,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":52,"referenced_works":["https://openalex.org/W1563577784","https://openalex.org/W1567484043","https://openalex.org/W1605253652","https://openalex.org/W1614648489","https://openalex.org/W1969818579","https://openalex.org/W1973454407","https://openalex.org/W1980927217","https://openalex.org/W1981229807","https://openalex.org/W1981674391","https://openalex.org/W1983236550","https://openalex.org/W1984779705","https://openalex.org/W2001519848","https://openalex.org/W2002178066","https://openalex.org/W2002220979","https://openalex.org/W2009870147","https://openalex.org/W2015491242","https://openalex.org/W2030922722","https://openalex.org/W2031628939","https://openalex.org/W2032731042","https://openalex.org/W2046503049","https://openalex.org/W2054883607","https://openalex.org/W2055339871","https://openalex.org/W2058839898","https://openalex.org/W2061385654","https://openalex.org/W2062946502","https://openalex.org/W2065639752","https://openalex.org/W2069236338","https://openalex.org/W2072171359","https://openalex.org/W2079749507","https://openalex.org/W2098223746","https://openalex.org/W2098537346","https://openalex.org/W2100772783","https://openalex.org/W2101217991","https://openalex.org/W2105649880","https://openalex.org/W2110523622","https://openalex.org/W2111872404","https://openalex.org/W2116292316","https://openalex.org/W2117926449","https://openalex.org/W2121008892","https://openalex.org/W2126087693","https://openalex.org/W2131666890","https://openalex.org/W2132049460","https://openalex.org/W2132776121","https://openalex.org/W2140377714","https://openalex.org/W2150129386","https://openalex.org/W2152673913","https://openalex.org/W2158649716","https://openalex.org/W2163087340","https://openalex.org/W2171784256","https://openalex.org/W2318430825","https://openalex.org/W2322458508","https://openalex.org/W2329694862"],"related_works":["https://openalex.org/W4362521660","https://openalex.org/W2509054882","https://openalex.org/W2300599593","https://openalex.org/W3156984470","https://openalex.org/W2529605118","https://openalex.org/W4415700318","https://openalex.org/W2981666147","https://openalex.org/W2320414642","https://openalex.org/W2988722150","https://openalex.org/W2914209107"],"abstract_inverted_index":{"INTRODUCTION:":[0],"The":[1,100],"JAK":[2,36,71,81,97,127,162],"kinases":[3,11,37],"are":[4,38,88,113,117,129],"a":[5,14,59],"family":[6],"of":[7,30,35,41,51,61,119,134,145,176,202],"four":[8,80],"tyrosine":[9],"receptor":[10,19],"that":[12,91],"play":[13],"pivotal":[15],"role":[16],"in":[17,105,122,131,165],"cytokine":[18],"signalling":[20],"pathways":[21],"via":[22],"their":[23],"interaction":[24],"with":[25,90,152,169],"signal":[26],"transducers":[27],"and":[28,65,86,111,154,197],"activators":[29],"transcription":[31],"proteins.":[32],"Selective":[33],"inhibitors":[34,72,82,121,128,141,163],"viewed":[39],"as":[40,44,116,137],"considerable":[42],"potential":[43],"disease-modifying":[45],"anti-inflammatory":[46],"drugs":[47],"for":[48,69,79,93],"the":[49,62,94,120,132,143,193],"treatment":[50,133],"rheumatoid":[52,135],"arthritis.":[53],"AREAS":[54],"COVERED:":[55],"This":[56],"article":[57],"provides":[58,192],"review":[60],"clinical":[63,67],"development":[64],"available":[66],"results":[68],"those":[70],"currently":[73],"under":[74],"investigation.":[75],"Phase":[76],"II":[77],"data":[78,102],"(baricitinib,":[83],"decernotinib,":[84],"filgotinib":[85],"INCB-039110)":[87,181],"contrasted":[89],"reported":[92],"recently":[95],"approved":[96],"inhibitor":[98],"tofacitinib.":[99],"preclinical":[101,123],"on":[103],"these,":[104],"addition":[106],"to":[107,148,187,198],"peficitinib,":[108],"ABT-494,":[109],"INCB-047986":[110],"AC-410":[112],"also":[114],"discussed,":[115],"some":[118],"development.":[124],"EXPERT":[125],"OPINION:":[126],"effective":[130,157],"arthritis":[136],"evidenced":[138],"by":[139,173],"several":[140],"enabling":[142],"majority":[144],"treated":[146],"patients":[147],"achieve":[149],"ACR20":[150],"responses,":[151],"baricitinib":[153],"INCB-039110":[155],"both":[156],"when":[158],"administered":[159],"once":[160],"daily.":[161],"differ":[164],"isoform":[166],"specificity":[167],"profiles,":[168],"good":[170],"efficacy":[171],"achievable":[172],"selective":[174],"inhibition":[175,201],"either":[177],"JAK1":[178],"(filgotinib":[179],"or":[180,182],"JAK3":[183],"(decernotinib).":[184],"It":[185],"remains":[186],"be":[188,205],"seen":[189],"what":[190,199],"selectivity":[191],"optimal":[194],"side-effect":[195],"profile":[196],"extent":[200],"JAK2":[203],"should":[204],"avoided.":[206]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2096906176","counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":9},{"year":2024,"cited_by_count":9},{"year":2023,"cited_by_count":7},{"year":2022,"cited_by_count":18},{"year":2021,"cited_by_count":10},{"year":2020,"cited_by_count":17},{"year":2019,"cited_by_count":20},{"year":2018,"cited_by_count":16},{"year":2017,"cited_by_count":16},{"year":2016,"cited_by_count":22},{"year":2015,"cited_by_count":14},{"year":2014,"cited_by_count":2}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
